Regulus Therapeutics
RGLS
#7200
Rank
โ‚ฌ0.51 B
Marketcap
7,44ย โ‚ฌ
Share price
0.00%
Change (1 day)
464.66%
Change (1 year)

Regulus Therapeutics (RGLS) - Total debt

Total debt on the balance sheet as of March 2025 : โ‚ฌ1.27 Million

According to Regulus Therapeutics's latest financial reports the company's total debt is โ‚ฌ1.27 Million. A companyโ€™s total debt is the sum of all current and non-current debts.

Regulus Therapeutics - Total debt on balance sheet (from 2011 to 2025)

Total debt by year

Year Total debt Change
2024-12-31โ‚ฌ0.26 M-87.82%
2023-12-31โ‚ฌ2.16 M-63.08%
2022-12-31โ‚ฌ5.85 M-6.5%
2021-12-31โ‚ฌ6.26 M65.53%
2020-12-31โ‚ฌ3.78 M-71.04%
2019-12-31โ‚ฌ13.06 M-9.86%
2018-12-31โ‚ฌ14.48 M-12.46%
2017-12-31โ‚ฌ16.55 M-12.08%
2016-12-31โ‚ฌ18.82 M
2014-12-31โ‚ฌ19.23 M135.55%
2013-12-31โ‚ฌ8.16 M6.61%
2012-12-31โ‚ฌ7.66 M-0.51%
2011-12-31โ‚ฌ7.7 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Sanofi
SNY
โ‚ฌ24.52 B 1,920,528.12%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚ฌ7.61 B 596,266.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ40.83 B 3,198,329.69%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ29.38 B 2,301,042.04%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚ฌ28.65 B 2,243,861.46%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
โ‚ฌ17.61 M 1,279.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚ฌ1.15 B 89,977.80%๐Ÿ‡บ๐Ÿ‡ธ USA